Anti-HIV-1 gp120 VHH Single Domain Antibody is a recombinant protein produced in E. coli.
Figure 1 sdAb binding pattern on different conformations and strains of HIV-1 Env followed by ELISA.
sdAbs binding to gp120 (bound via the D7324 antibody to epoxybeads) or to gp140 (directly immobilized on epoxybeads) were detected via a peroxidase labeled anti-c-myc Ab. Histograms correspond to the three main families of sdAbs selected. JM3, JM4 and JM5 bind both Env forms while JM7 only binds to the cross-linked Env.
Matz, J., Kessler, P., Bouchet, J., Combes, O., Ramos, O. H. P., Barin, F., ... & Chames, P. (2013). Straightforward selection of broadly neutralizing single-domain antibodies targeting the conserved CD4 and coreceptor binding sites of HIV-1 gp120. Journal of virology, 87(2), 1137-1149.
Figure 2 sdAb neutralization ability toward different pseudovirions strains.
Each sdAb was tested in a single-round neutralization assay as described in the "Materials and Methods" section using TZM-bl cells as target cells. Pseudovirions (100 TCID50) carrying various envelope glycoproteins from different HIV-1 subtypes were pre-incubated in 96-well plates for 1 h at 37°C with purified sdAbs at 10 µM.
Matz, J., Kessler, P., Bouchet, J., Combes, O., Ramos, O. H. P., Barin, F., ... & Chames, P. (2013). Straightforward selection of broadly neutralizing single-domain antibodies targeting the conserved CD4 and coreceptor binding sites of HIV-1 gp120. Journal of virology, 87(2), 1137-1149.
Figure 3 Competition between sdAbs and phage-sdAbs on gp140 or gp140-S-S-M64U1 followed by ELISA.
10 µg/ml of sdAbs, X5 and b12 were added to immobilized Env as indicated in the "Materials and Methods". After 1 h, phage-sdAbs were added at subsaturating concentration. Bound phage-sdAbs were revealed using peroxidase labeled anti-M13 antibody.
Matz, J., Kessler, P., Bouchet, J., Combes, O., Ramos, O. H. P., Barin, F., ... & Chames, P. (2013). Straightforward selection of broadly neutralizing single-domain antibodies targeting the conserved CD4 and coreceptor binding sites of HIV-1 gp120. Journal of virology, 87(2), 1137-1149.
Figure 4 Competition between sdAbs and phage-sdAbs on gp140 or gp140-S-S-M64U1 followed by ELISA.
10 µg/ml of sdAbs, X5 and b12 were added to immobilized Env as indicated in the "Materials and Methods". After 1 h, phage-sdAbs were added at subsaturating concentration. Bound phage-sdAbs were revealed using peroxidase labeled anti-M13 antibody. Competition was done on gp140-S-S-M64U1.
Matz, J., Kessler, P., Bouchet, J., Combes, O., Ramos, O. H. P., Barin, F., ... & Chames, P. (2013). Straightforward selection of broadly neutralizing single-domain antibodies targeting the conserved CD4 and coreceptor binding sites of HIV-1 gp120. Journal of virology, 87(2), 1137-1149.
Figure 5 sdAb binding to complexed or uncomplexed Env followed by SPR.
sdAbs were immobilized on sensorchip CM5. Using a Biacore 3000 instrument, Env was injected at various concentrations on different channels. Uncomplexed gp140 and gp140 + M48U1 complex were run over immobilized JM4, JM5 and JM7.
Matz, J., Kessler, P., Bouchet, J., Combes, O., Ramos, O. H. P., Barin, F., ... & Chames, P. (2013). Straightforward selection of broadly neutralizing single-domain antibodies targeting the conserved CD4 and coreceptor binding sites of HIV-1 gp120. Journal of virology, 87(2), 1137-1149.
Figure 6 sdAb epitope mapping using Env mutants by ELISA.
sdAb was assessed for its ability to bind WT Env (pink line), CD4BS mutant D368R (orange line), CoRBS mutant I420R (blue line) and triple mutant I423M, N425K and G431E (green line), in the presence of miniCD4 M48U1, except for JM2.
Matz, J., Kessler, P., Bouchet, J., Combes, O., Ramos, O. H. P., Barin, F., ... & Chames, P. (2013). Straightforward selection of broadly neutralizing single-domain antibodies targeting the conserved CD4 and coreceptor binding sites of HIV-1 gp120. Journal of virology, 87(2), 1137-1149.
This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:
• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production
See more details about Hi-Affi™ recombinant antibody benefits.
Download resources about recombinant antibody development and antibody engineering to boost your research.
Select a product category from the dropdown menu below to view related products.
CAT | Product Name | Application | Type |
---|---|---|---|
AGTO-L012R | anti-env immunotoxin 907 (IgG)-RTA | Cytotoxicity assay, Functional assay |
There are currently no Customer reviews or questions for PNBL-020. Click the button above to contact us or submit your feedback about this product.
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.